Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease

详细信息    查看全文

• 作者：Stephanie M Patton (1)
  Yong Won Cho (2)
  Thomas W Clardy (1)
  Richard P Allen (3)
  Christopher J Earley (3)
  James R Connor (1)
  
• 关键词：Sleep disorders ; Restless legs syndrome/Willis ; Ekbom disease ; Nitric oxide ; Hypoxia inducible factor ; Pain
• 刊名：Fluids and Barriers of the CNS
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：10
• 期：1
• 全文大小：252KB
• 参考文献：1. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L: Restless legs syndrome prevalence and impact: REST general population study. / Arch Intern Med 2005, 165:1286-292. CrossRef
  2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. / Sleep Med 2003, 4:101-19. CrossRef
  3. Earley CJ, Silber MH: Restless legs syndrome: understanding its consequences and the need for better treatment. / Sleep Med 2010, 11:807-15. CrossRef
  4. Ulfberg J, Nystrom B, Carter N, Edling C: Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. / Mov Disord 2001, 16:1159-163. CrossRef
  5. Winkelman JW, Finn L, Young T: Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. / Sleep Med 2006, 7:545-52. CrossRef
  6. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ: Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. / Neurology 2008, 70:35-2. CrossRef
  7. Ohayon MM, Roth T: Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. / J Psychosom Res 2002, 53:547-54. CrossRef
  8. Allen RP, Earley CJ: The role of iron in restless legs syndrome. / Mov Disord 2007,22(Suppl 18):S440-S448. CrossRef
  9. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ: MRI measurement of brain iron in patients with restless legs syndrome. / Neurology 2001, 56:263-65. CrossRef
  10. Godau J, Klose U, Di Santo A, Schweitzer K, Berg D: Multiregional brain iron deficiency in restless legs syndrome. / Mov Disord 2008, 23:1184-187. CrossRef
  11. Cho YW, Shin WC, Yun CH, Hong SB, Kim JH, Allen RP, Earley CJ: Epidemiology of restless legs syndrome in Korean adults. / Sleep 2008, 31:219-23.
  12. Hening WA, Allen RP, Washburn M, Lesage S, Earley CJ: Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. / Sleep Med 2008, 9:283-89. CrossRef
  13. Geguchadze RN, Coe CL, Lubach GR, Clardy TW, Beard JL, Connor JR: CSF proteomic analysis reveals persistent iron deficiency-induced alterations in non-human primate infants. / J Neurochem 2008, 105:127-36. CrossRef
  14. Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, Allen RP: Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. / Neurology 2004, 62:1563-567. CrossRef
  15. Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP: Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. / Sleep 2005, 28:1069-075.
  16. Allen RP, Connor JR, Hyland K, Earley CJ: Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. / Sleep Med 2009, 10:123-28. CrossRef
  17. Liu XD, Zeng BF, Xu JG, Zhu HB, Xia QC: Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. / Proteomics 2006, 6:1019-028. CrossRef
  18. Mannes AJ, Martin BM, Yang HY, Keller JM, Lewin S, Gaiser RR, Iadarola MJ: Cystatin C as a cerebrospinal fluid biomarker for pain in humans. / Pain 2003, 102:251-56. CrossRef
  19. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, Knight H: Evaluating the quality of life of patients with restless legs syndrome. / Clin Ther 2004, 26:925-35. CrossRef
  20. Edwards RR, Quartana PJ, Allen RP, Greenbaum S, Earley CJ, Smith MT: Alterations in pain responses in treated and untreated patients with restless legs syndrome: associations with sleep disruption. / Sleep Med 2011, 12:603-09. CrossRef
  21. Yunus MB: Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. / Best Pract Res Clin Rheumatol 2007, 21:481-97. CrossRef
  22. D'Onofrio F, Bussone G, Cologno D, Petretta V, Buzzi MG, Tedeschi G, Bonavita V, Cicarelli G: Restless legs syndrome and primary headaches: a clinical study. / Neurol Sci 2008,29(Suppl 1):S169-S172. CrossRef
  23. Weinstock LB, Walters AS, Paueksakon P: Restless legs syndrome–theoretical roles of inflammatory and immune mechanisms. / Sleep Med Rev 2012, 16:341-54. CrossRef
  24. Jordan W, Tumani H, Cohrs S, Eggert S, Rodenbeck A, Brunner E, Ruther E, Hajak G: Prostaglandin D synthase (beta-trace) in healthy human sleep. / Sleep 2004, 27:867-74.
  25. Jordan W, Hagedohm J, Wiltfang J, Laier-Groeneveld G, Tumani H, Rodenbeck A, Ruther E, Hajak G: Biochemical markers of cerebrovascular injury in sleep apnoea syndrome. / Eur Respir J 2002, 20:158-64. CrossRef
  26. Barcelo A, de la Pena M, Barbe F, Pierola J, Bosch M, Agusti AG: Prostaglandin D synthase (beta trace) levels in sleep apnea patients with and without sleepiness. / Sleep Med 2007, 8:509-11. CrossRef
  27. Patton SM, Ponnuru P, Snyder AM, Podskalny GD, Connor JR: Hypoxia-inducible factor pathway activation in restless legs syndrome patients. / Eur J Neurol 2011, 18:1329-335. CrossRef
  28. Speeckaert M, Huang G, Delanghe JR, Taes YE: Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. / Clin Chim Acta 2006, 372:33-2. CrossRef
  29. Gomme PT, Bertolini J: Therapeutic potential of vitamin D-binding protein. / Trends Biotechnol 2004, 22:340-45. CrossRef
  30. Qin Z, Qin Y, Liu S: Alteration of DBP levels in CSF of patients with MS by proteomics analysis. / Cell Mol Neurobiol 2009, 29:203-10. CrossRef
  31. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ: CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. / Am J Clin Pathol 2008, 129:526-29. CrossRef
  32. Baksi SN, Hughes MJ: Chronic vitamin D deficiency in the weanling rat alters catecholamine metabolism in the cortex. / Brain Res 1982, 242:387-90. CrossRef
  33. Masuhara T, Migicovsky BB: Vitamin D and the intestinal absorption of iron and cobalt. / J Nutr 1963, 80:332-36.
  34. Balaban H, Yildiz OK, Cil G, Senturk IA, Erselcan T, Bolayir E, Topaktas S: Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. / Sleep Med 2012, 13:953-57. CrossRef
  35. Biagioli M, Pinto M, Cesselli D, Zaninello M, Lazarevic D, Roncaglia P, Simone R, Vlachouli C, Plessy C, Bertin N, / et al.: Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. / Proc Natl Acad Sci USA 2009, 106:15454-5459. CrossRef
  36. Turjanski N, Lees AJ, Brooks DJ: Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. / Neurology 1999, 52:932-37. CrossRef
  37. Cervenka S, Palhagen SE, Comley RA, Panagiotidis G, Cselenyi Z, Matthews JC, Lai RY, Halldin C, Farde L: Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. / Brain 2006, 129:2017-028. CrossRef
  38. Kim KW, Jhoo JH, Lee SB, Lee SD, Kim TH, Kim SE, Kim YK, Yoon IY: Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. / Eur J Neurol 2012, 19:1213-218. CrossRef
  39. Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U: Characterization of four lipoprotein classes in human cerebrospinal fluid. / J Lipid Res 2001, 42:1143-151.
  40. Winter AC, Berger K, Glynn RJ, Buring JE, Gaziano JM, Schurks M, Kurth T: Vascular risk factors, cardiovascular disease, and restless legs syndrome in men. / Am J Med 2013, 126:228-35 e222. CrossRef
  41. Schlesinger I, Erikh I, Avizohar O, Sprecher E, Yarnitsky D: Cardiovascular risk factors in restless legs syndrome. / Mov Disord 2009, 24:1587-592. CrossRef
  42. Chen GL, Liu LW, Xie S, Liu H, Liu YQ, Li YS: High-density lipoprotein associated factors apoA-I and serum amyloid A in Chinese non-diabetic patients with coronary heart disease. / Chin Med J (Engl) 2010, 123:658-63.
  43. Moshage H: Cytokines and the hepatic acute phase response. / J Pathol 1997, 181:257-66. CrossRef
  44. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. / Proc Natl Acad Sci USA 2006, 103:1834-839. CrossRef
  45. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. / Nature 2004, 432:917-21. CrossRef
  46. Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J: CSF iron, ferritin and transferrin levels in restless legs syndrome. / J Sleep Res 2005, 14:43-7. CrossRef
  47. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, Earley CJ: Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. / Neurology 2003, 61:304-09. CrossRef
  
• 作者单位：Stephanie M Patton (1)
  Yong Won Cho (2)
  Thomas W Clardy (1)
  Richard P Allen (3)
  Christopher J Earley (3)
  James R Connor (1)
  
  1. Department of Neurosurgery, Penn State University, Milton S. Hershey Medical Center, 500 University Drive, Hershey, Pennsylvania PA, 17033, USA
  2. DongSan Medical Center, Keimyung University, Taegu, Korea
  3. Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
  

文摘

Background Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a sensorimotor disorder that causes patients to experience overwhelming and distressing sensations in the legs compelling the patient to move their legs to provide relief. The purpose of this study was to determine if biomarkers in the cerebrospinal fluid can distinguish RLS/WED patients from neurological controls. Methods We obtained CSF samples by lumbar puncture from 5 early-onset RLS/WED patients and 5 controls. We performed 2-dimensional difference in-gel electrophoresis (2D-DIGE). Proteins that were significantly altered were identified by Student’s t-test. Protein spots that were differentially expressed (p ?0.05, Av. Ratio ?2.0) between RLS/WED and control CSF samples were identified using MALDI-TOF-MS. Statistical analyses of the validation immunoblot assays were performed using Student’s t-test. Results In this discovery study we identified 6 candidate CSF protein markers for early-onset RLS/WED. Four proteins (Cystatin C, Lipocalin-type Prostaglandin D2 Synthase, Vitamin D binding Protein, and β-Hemoglobin) were increased and 2 proteins (Apolipoprotein A1 and α-1-acid Glycoprotein) were decreased in RLS/WED patients. Conclusions Our results reveal a protein profile in the RLS/WED CSF that is consistent with clinical findings of disruptive sleep, cardiovascular dysfunction and painful symptoms. Moreover, protein profiles are consistent with neuropathological findings of activation of hypoxia inducible factor (HIF) pathways and alterations in dopaminergic systems. These data indicate the CSF of RLS/WED patients may provide information relevant to biological basis for RLS/WED, treatment strategies and potential new treatment targets.